Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Alderson

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Archives of Biochemistry and Biophysics|April 28, 2004
Chemical modification of muscle protein in diabetesNadja Alt, James A Carson, Nathan L Alderson, et al.
Oral and Maxillofacial Surgery|October 7, 2021
The effect of lockdown during SARS-CoV-2 pandemic on maxillofacial injuries in a level I trauma centre: a comparative studyBasim E S Dawoud, L Alderson, U Khan, et al.
Medicine and Science in Sports and Exercise|October 1, 1996
Effect of a single session of exercise on lipoprotein(a)J L Durstine, M A Ferguson, L M Szymanski, et al.
BMJ Open|November 25, 2020
Improving the Safety and Continuity Of Medicines management at Transitions of care (ISCOMAT): protocol for a process evaluation of a cluster randomised control trialCatherine Powell, Liz Breen, Beth Fylan, et al.
The Journal of Biological Chemistry|August 13, 2008
Regulation of telomere length by fatty acid elongase 3 in yeast. Involvement of inositol phosphate metabolism and Ku70/80 functionSuriyan Ponnusamy, Nathan L Alderson, Hiroko Hama, et al.
Frontiers in Pharmacology|May 25, 2012
Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastomaTony A Koehn, Lori L Trimble, Kory L Alderson, et al.
Metabolism: Clinical and Experimental|July 29, 2004
In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetesAlicia J Jenkins, Suzanne R Thorpe, Nathan L Alderson, et al.
Kidney International|February 19, 2002
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic ratThorsten P Degenhardt, Nathan L Alderson, David D Arrington, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|August 1, 2022
Experiences of patients with heart failure with medicines at transition intervention: Findings from the process evaluation of the Improving the Safety and Continuity of Medicines management at Transitions of care (ISCOMAT) programmeCatherine Powell, Hanif Ismail, Maureen Davis, et al.
Diabetologia|August 17, 2004
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic ratN L Alderson, M E Chachich, N Frizzell, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Archives of Biochemistry and Biophysics|April 28, 2004
Chemical modification of muscle protein in diabetesNadja Alt, James A Carson, Nathan L Alderson, et al.
Oral and Maxillofacial Surgery|October 7, 2021
The effect of lockdown during SARS-CoV-2 pandemic on maxillofacial injuries in a level I trauma centre: a comparative studyBasim E S Dawoud, L Alderson, U Khan, et al.
Medicine and Science in Sports and Exercise|October 1, 1996
Effect of a single session of exercise on lipoprotein(a)J L Durstine, M A Ferguson, L M Szymanski, et al.
BMJ Open|November 25, 2020
Improving the Safety and Continuity Of Medicines management at Transitions of care (ISCOMAT): protocol for a process evaluation of a cluster randomised control trialCatherine Powell, Liz Breen, Beth Fylan, et al.
The Journal of Biological Chemistry|August 13, 2008
Regulation of telomere length by fatty acid elongase 3 in yeast. Involvement of inositol phosphate metabolism and Ku70/80 functionSuriyan Ponnusamy, Nathan L Alderson, Hiroko Hama, et al.
Frontiers in Pharmacology|May 25, 2012
Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastomaTony A Koehn, Lori L Trimble, Kory L Alderson, et al.
Metabolism: Clinical and Experimental|July 29, 2004
In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetesAlicia J Jenkins, Suzanne R Thorpe, Nathan L Alderson, et al.
Kidney International|February 19, 2002
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic ratThorsten P Degenhardt, Nathan L Alderson, David D Arrington, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|August 1, 2022
Experiences of patients with heart failure with medicines at transition intervention: Findings from the process evaluation of the Improving the Safety and Continuity of Medicines management at Transitions of care (ISCOMAT) programmeCatherine Powell, Hanif Ismail, Maureen Davis, et al.
Diabetologia|August 17, 2004
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic ratN L Alderson, M E Chachich, N Frizzell, et al.
Pageof 15